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Abstract: Recent findings highlight the emerging role of the endocannabinoid system in the control
of symptoms and disease progression in multiple sclerosis (MS). MS is a chronic, immune-mediated,
demyelinating disorder of the central nervous system with no cure so far. It is widely reported in the
literature that cannabinoids might be used to control MS symptoms and that they also might exert
neuroprotective effects and slow down disease progression. This review aims to give an overview of
the principal cannabinoids (synthetic and endogenous) used for the symptomatic amelioration of MS
and their beneficial outcomes, providing new potentially possible perspectives for the treatment of
this disease.
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1. Introduction
Multiple sclerosis (MS) is an important neurological disease that affects the central nervous
system (CNS). It is the most common neurological disorder in young adults and affects approximately
2.3 million people worldwide [1]. It is more common in women than in men [2,3], with a prevalence
ratio of 3:1 [4,5]. Regarding its etiology, it is now widely accepted that genetic and environmental
factors may contribute to the onset and development of the disease [6,7]. MS is a chronic inflammatory
immune-mediated condition characterized by demyelination of the axons in the CNS. It gradually
leads to progressive neurodegeneration that damages CNS myelin, leading to neuronal dysfunction
and a broad spectrum of neurological symptoms that depend upon the site where lesions have occurred
in the brain and spinal cord. The symptoms of MS include spasticity, sensory alterations, weakness,
painful spasms, bladder dysfunction, tremor, ataxia, optic neuritis, fatigue, and dysphagia [8].
On the basis of the understanding of the disease process in MS and of magnetic resonance
imaging (MRI) technology, in 1996, the International Advisory Committee on Clinical Trials of
MS, classified MS into four independent subtypes [9]: (1) relapsing-remitting MS (RRMS), which
is the most common form of MS (approximately 85%–90% of all cases) [8] and it is typified by
unpredictable relapses with full recovery or with sequelae; (2) secondary progressive MS (SPMS),
which follows generally RRMS (approximately 65% of RRMS patients will evolve to SPMS), progressing
and leading to neurological damages and consequently physical decline of the patient without
remission [10]; (3) primary-progressive MS (PPMS) which is diagnosed in approximately 10%–15% of
patients [8] and progresses continuously from the onset without attacks; and (4) progressive-relapsing
MS (PRMS) which is the least common subtype of MS, includes approximately 5% of all cases of
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MS and characterized by a steady decline onset with super-imposed attacks. However, in 2013,
the Committee revised the classification, retaining the basics of 1996 MS phenotypes description,
with some modifications and clarifications. These include the elimination of the PRMS category,
since subjects so categorized would be classified as PP patients (PP-active if acute attacks are present,
PP-inactive if no acute attacks occur), and the inclusion of the clinically isolated syndrome (CIS)
recognized as the first clinical presentation of a disease that shows characteristics of inflammatory
demyelination that, if subsequently active and fulfilling MS diagnostic criteria, becomes RRMS [11].
Molecular mechanisms of MS progression remain unclear. However, the observed hallmarks
are considered as consequence of three synergistically mechanisms: inflammation, demyelination,
and axonal damage. Recent evidence indicates that MS is primarily a neurodegenerative disease
that starts in the brain and then develops because of inflammation [12]. This hypothesis has led
to two models of MS immune-pathogenesis: the “inside-out” and “outside-in.” In the first model,
a dysfunction of brain cells causes the immune response that destroys myelin and leads to blood-brain
barrier (BBB) breakdown. In the second model, a dysfunction of the periphery leads to BBB damage,
myelin disruption, and axonal death [13]. The subsequent high presence of lymphocytes in the
CNS and the activation of innate immune cells (dendritic cell, macrophages, microglia) play key
roles in MS pathogenesis. The activation of autoimmune cells, resident microglia, astrocytes and
macrophages, results in an immunological storm that involves abundant secretion of reactive species,
cytokines, chemokines, autoantibody production, and enhanced excitotoxicity. There is a continuing
activation of resident microglia and astrocytes producing pro-inflammatory mediators that potentiate
the neuroinflammatory response. This results in oligodendrocytes and axonal damage and ultimately
in demyelination, synaptic alteration, and neuronal loss [8,14–16]. In the early phases of MS, the
oligodendrocytes generate new myelin, and this remyelination is one of the reasons why symptoms
decrease or temporarily disappear in RRMS [17]. However, the myelin sheaths are not completely
rebuilt by oligodendrocytes, and repeated attacks lead to damage in the axons where scar-like plaques
build up with subsequent axonal loss [18], associated with the characteristic symptoms of MS [19].
At present, there are three categories of available drug therapies for MS: treatment of clinical
attacks (acute relapses), disease-modifying, and symptomatic therapies.
The first-line treatment of acute relapses in MS consists of intravenous administration of high
doses of corticosteroids, specifically methylprednisolone (MP) [20]. For patients who do not improve or
cannot tolerate MP, there is a second line therapeutic option that is represented by adrenocorticotropic
hormone (ACTH) in a gel formulation administered either intramuscularly or subcutaneously [20,21].
Disease-modifying therapies (DMTs) are aimed to reduce the relapses in terms of number,
duration, and gravity while maintaining remission and slowing progression. These therapies also
reduce disability, MRI lesions, and should improve the quality of life of MS patients. First-generation
injectable DMTs that are currently approved by the Food and Drug Administration (FDA) include
four interferon beta formulations and glatiramer acetate. Four orals (fingolimod, teriflunomide,
dimethyl fumarate, and cladribine) and three monoclonal antibodies (natalizumab, alemtuzumab, and
ocrelizumab, all intravenous injectables) are also indicated for MS treatment [22–26].
Interferon beta, glatiramer acetate, teriflunomide, and dimethyl fumarate are considered first-line
therapies, while natalizumab and alemtuzumab are second-line drugs. In the European Union,
fingolimod is approved as a second-line treatment, while in the United States, Canada and other
countries it is a first-line drug [27].
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Symptomatic therapies that relieve the distressing and/or disabling symptoms of multiple
sclerosis include muscle relaxants for spasticity (baclofen, tizanidine, dantrolene sodium,
benzodiazepines), anticonvulsants for neuropathic pain (diazepam, clonazepam, gabapentin,
pregabalin) [28,29], and anticholinergic drugs for bladder dysfunction and dysphagia (oxybutynin,
propantheline) [8,30,31]. However, limitations of these therapeutic options result from their incomplete
effectiveness in managing such complex symptoms and adverse reactions associated with their
prolonged use [32,33]. A therapeutic option for patients with severe refractory spasticity is the
intrathecal delivery of baclofen via an implanted pump, although the procedure is invasive, expensive,
and not free of possible complications (pump dysfunction, infection). Moreover, intramuscular
botulinum toxin injections have been shown to be effective in the case of focal spasticity [33,34].
Finally, a temporary reduction in spasticity can be obtained by blocking peripheral nerves with phenol
injections [35].
Over the last 15 years, a great amount of preclinical studies has demonstrated that compounds
targeting the endocannabinoid system (ECS) exert anti-inflammatory properties and neuroprotective
and immuno-modulatory effects [36], allowing them to alleviate symptoms and to limit progressive
neurodegeneration in animal models of MS [37].
The endocannabinoid system consists of two G protein-coupled receptors, the type-1 (CB1R)
and type-2 (CB2R) cannabinoid receptor, a class of lipids mediators called endocannabinoids (ECs),
and several enzymes involved in the biosynthesis and degradation of ECs. The most well-studied
ECs are N-arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) [38].
The biological activities of these lipid mediators are terminated upon cellular re-uptake and subsequent
metabolism. The main metabolic enzymes of ECs are fatty acid amide hydrolase (FAAH) that degrades
AEA into arachidonic acid (AA) and ethanolamine [39] and monoacylglycerol lipase (MAGL) that
degrades 2-AG in AA and glycerol [40].
The aim of this review is to highlight the role of ECS in MS. In the first part, it will concern
medicinal cannabinoids that are licensed for MS treatment. Subsequently, the main classes of ECS
modulators described in the literature will be reviewed, focusing on their mode of action and on
obtained results in preclinical studies that highlight their potential translational aspects for MS.
2. Medicinal Cannabinoids
Scientific research concerning the use of cannabinoids to manage MS symptoms has been
stimulated by anecdotal reports of MS patients that experience symptomatic relief after smoking
cannabis [41]. These evidence have produced a considerable interest for taking cannabinoid-based
medicines into clinical practice for the treatment of both relapsing-remitting and progressive forms
of MS. Therefore, various cannabinoid preparations have been examined in several clinical studies
to assess their efficacy in symptomatic treatment of MS and other neurological disorders in human
patients [42]. The medicinal grade cannabinoids that are licensed for MS treatment change from
country to country. Off-label use also varies widely [42–44].
Currently, the three main licensed cannabinoid preparations are Marinol® (whose active principle
is dronabinol), Cesamet® (whose active principle is nabilone, Table 1), and Sativex® (whose active
principle is nabixiomls, i.e., a standardized~1:1 (w/w) mix of ∆9-tetrahydrocannabinol (∆9-THC)
(Table 1) and cannabidiol (CBD), both extracted from Cannabis sativa) (Table 1). There are also other
preparations based on natural cannabinoids containing different quantitative ratios of of ∆9-THC and
CBD, i.e., Bedrocan® (22% ∆9-THC, <1% CBD from Cannabis sativa), Bedrobinol® (13.5% ∆9-THC,
<1% CBD from Cannabis sativa), Bediol® (6.5% ∆9-THC, 8% CBD from Cannabis sativa), Bedica® (14%
∆9-THC, <1% CBD from Cannabis indica), Bedrolite® (<1% ∆9-THC, 9% CBD from Cannabis sativa),
Bedropuur® (20%–24% ∆9-THC, <1% CBD from Cannabis indica).
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Table 1. Summary of clinical evidence of dronabinol, nabilone, and nabiximols.
Dronabinol
(Synthetic∆9-THC)
Nabilone (Synthetic
Analogue of ∆9-THC)
Nabiximols (∆9-THC:
Cannabidiol~1:1 (w/w))
Structure(s)
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Formulation Soft gelatin capsules(2.5, 5, 10 mg) Capsules (0.25, 0.5, 1 mg)
Oro-mucosal spray (27 mg
of ∆9-THC and 25 mg of
cannabidiol/1.0 mL)
Disability and disease
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Spasticity Mixed findings Positive effects Mixed findings (mostlypositive effects)
Bladder function Mixed findings Positive effects Mixed findings
Ataxia and tremor No evident changes No studies No evident changes
Sleep Mixed findings (mostlypositive effects) No studies Positive effects
Quality of life Mixed findings Mixed findings (mosltypositive effects) Mixed findings
Adverse effects
Mild to moderate.
Principally dizziness,
euphoria, dry mouth,
fatigue and drowsiness.
Moderate sedation,
dizziness and moderate
weakness in the legs.
Mild to moderate.
Principally drowsiness,
dizziness, headache, fatigue,
impaired balance and
disturbance in attention.
Number of studies 10 3 11
Number of reviews 11 5 12
Studies (references) [45–54] [55–57] [58–68]
Reviews (references) [33,69–78] [69,70,72,73,78] [69,70,72–81]
2.1. Dronabinol
“Dronabinol” is the generic official name for the synthetically obtained pure isomer of THC,
(−)-trans-∆9-tetrahydrocannabinol, the main THC isomer found in the cannabis plant. It was originally
developed for the treatment of chemotherapy-induced nausea and vomiting (CINV). Its use was then
extended to anorexia associated to weight loss in AIDS patients.
It is available in oral soft gelatin capsules with a range of three dosage (2.5, 5, and 10 mg).
Dronabinol has been specifically evaluated for its effectiveness and safety in treating MS symptoms in
10 clinical studies published between 1981 and 2013 [45–54]; almost all of these studies are reported in
10 reviews published between 2003 and 2016 [33,69–77] that have been included in a systematic review
of reviews on the basis of eligibility criteria of methodological quality (AMSTAR Tool: A MeaSurement
Tool to Assess systematic Reviews) [78]. Eight key clinical outcomes in MS have been considered to
provide an overview of the current findings about dronabinol, i.e. disability/disease progression, pain,
spasticity, bladder function, ataxia/tremor, sleep, quality of life, and adverse effects [78]. A summary
of clinical evidence for dronabinol is shown in Table 1.
Positive effects have been found mainly with regard to pain associated with MS [46,49–51].
Substantially, no change was noted in the assessment of ataxia and tremor [45–47]. Also regarding
to disability and disease progression, there are no evident changes [45–48,54] (noteworthy is the
recent CUPID study [54], which has provided a large amount of data regarding treatment with
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dronabinol, showing that it has no overall effect on the progression of MS). Indeed, in some cases,
negative effects have been detected [45]. Regarding the quality of sleep, there are mixed findings,
although they are mostly positive [46,50]. There are mixed findings also for the rest of the clinical
outcomes (spasticity [45,46,50–52], bladder function [46,53], and quality of life [45,46]). Adverse
effects to dronabinol have been described more frequently as mild to moderate; principally, they were
dizziness, euphoria, dry mouth, fatigue, and drowsiness [45–47,49–53]. Cognitive impairment did
not appear to be relevant, except in patients with pre-existing cognitive disfunctions [45,46,49,50,53].
Taken together, these results indicate that for dronabinol, the only significant clinical evidence relates
to its ability to relieve pain associated with MS, while for the rest, it can be concluded that evidence are
quite inconsistent.
2.2. Nabilone
Nabilone is a synthetic analogue of ∆9-THC bearing a dibenzopyran-9-one structure (Table 1). It is
a racemic mixture consisting of (S,S)-(+)- and (R,R)-(−)-isomers and was originally licensed in 1985
for the treatment of CINV in patients who failed to respond adequately to conventional antiemetic
treatments. The development of serotonin 5-HT3 receptor antagonists has partially supplanted the use
of nabilone for this therapeutic application.
In more recent years, some evidence has emerged about the use of nabilone for the treatment of
pain of various origin (e.g., neuropathic, chronic, cancer pain) and spasticity related to MS. However,
over the last two decades, there has been a minimal amount of research on its use beyond its license.
Nabilone is available as capsules in strengths of 0.25, 0.5, and 1 mg. It has been specifically evaluated
for its effectiveness and safety in treating MS symptoms in three clinical studies. These has been
published between 1995 and 2015 [55–57] and are reported in four reviews published between 2006
and 2015 [69,70,72,73] included in a systematic review of reviews on the basis of eligibility criteria of
methodological quality (AMSTAR Tool) [78]. As mentioned above, the eight MS clinical outcomes
considered were: disability/disease progression, pain, spasticity, bladder function, ataxia/tremor,
sleep, quality of life, and adverse effects [78]. A summary of clinical evidence of nabilone is showed in
Table 1.
Although the clinical trials are not abundant and the number of patients evaluated has been rather
low, positive effects due to nabilone were found regarding pain [55], spasticity [55,56], and bladder
dysfunction [55] associated to MS. Mixed findings, although mostly positive, resulted in the evaluation
of quality of life [55,57]. In fact, one study found a significant improvement in objective rating of
general health status [55]; in another study (in which nabilone was evaluated as an adjunctive drug to
gabapentin) was found an improvement in patient global impression of change, but no statistically
significant difference in “VASimpact” (impact of pain on patient’s daily activities, recorded using a
visual analog scale) was found between nabilone and placebo group [57]. No studies were conducted
about the effect of nabilone on sleep quality of MS patients and on disability/disease progression.
With regard to adverse reactions to nabilone, moderate sedation, dizziness, and moderate weakness in
the legs have been reported [55,56]. These data indicate that, for nabilone, there are specific positive
conclusions for three clinical outcomes related to MS, i.e. pain, spasticity and bladder problems.
2.3. Nabiximols
Nabiximols is a specific extract from cloned plants of Cannabis sativa, first approved in Canada in
2005 for the treatment of cancer pain and neuropathic pain in patients affected by MS. In the following
years, the drug was authorized in several European countries, and today, it is available in about 20
countries worldwide for the treatment of MS-related moderate to severe spasticity in patients who
have not responded adequately to other anti-spasticity therapies.
It consists of an approximate 1:1 fixed ratio of ∆9-THC and CBD [82]. It was developed in
response to widespread anecdotal reports that cannabis was a useful medicine for treating a number of
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MS-related symptoms. CBD, non-psychoactive isolated plant cannabinoid, was included in the drug
essentially to ameliorate side effects due to ∆9-THC.
Nabiximols is the active principle of the trade drug Sativex®, a pharmaceutical product
standardized in composition, formulation, and dosage. It is formulated as an oro-mucosal spray,
containing 27 mg of ∆9-THC and 25 mg of CBD/1.0 mL, in an aromatized water-ethanol solution.
Sativex® is available as 5.5 mL spray bottles (which deliver up to 48 sprays) or as 10 mL spray bottles
(which deliver up to 90 sprays). Each dose (spray or “puff”) delivers 0.1 mL of solution (2.7 mg of
∆9-THC and 2.5 mg of CBD). The oro-mucosal administration allows a slower absorption with respect
to inhalation, avoiding the high plasma levels that occur when cannabis is smoked or vaporized. On the
other hand, this route is more rapid and consistent than the oral administration [83], allowing rapid
and direct access to the circulation through the mucosa with a faster plateau of plasma concentration
and avoiding the problems of the oral route [79]. Moreover, the oro-mucosal formulation provides
a simple delivery system, allowing the patient to self-manage a convenient and accurate titration
of dosage.
Nabiximols has been widely evaluated for its effectiveness and safety in treating MS symptoms
in 11 clinical studies published between 2004 and 2014 [58–68]; these studies are reported in 11
reviews published between 2006 and 2017 [69,70,72–77,79–81]. Most of these reviews have been
included in a systematic review of reviews on the basis of eligibility criteria of methodological quality
(AMSTAR Tool) [78]. The eight main clinical outcomes in MS that have been included to provide an
overview of the current findings about nabiximols, are the same seen in the above paragraphs, i.e.,
disability/disease progression, pain, spasticity, bladder function, ataxia/tremor, sleep, quality of life,
and adverse effects [78]. A summary of clinical evidence of nabiximols is shown in Table 1.
Regarding MS-related pain, most evidence supports the use of nabiximols for this pathological
condition. In fact, in many randomized controlled trials (RCT) a significant reduction in numeric
rating scales (NRS) and visual analogic scales (VAS) score was highlighted in the treated group respect
to placebo group [58–65]. Some clinical evidence indicates that nabiximols is probably effective in
the treatment of spasticity associated with MS [58,59,66,67]. These data mainly concern the patient’s
subjective evaluation scales (NRS); in the objective evaluation scales, such as Ashworth scale (AS)
and modified Ashworth scale (MAS), the results are in favor of nabiximols but, in some cases, not
statistically significant [59,66]. However, in some studies, no change in spasticity was found [60,63].
There is some evidence that nabiximols is probably effective in reducing the number of bladder voids
per day [68], but contradictory results emerged about its efficacy in reducing overall bladder symptoms
related to MS [58,68]. Clinical studies carried out to date failed to demonstrate that nabiximols can
produce any significant positive change in MS-induced tremor and ataxia [58,59], while statistically
significant subjective improvement in sleep quality have been highlighted [58]. Regarding the quality
of life, there are in general mixed findings, although in some cases the average number of MS patients
treated with nabiximols who reported an improvement of the global impression of change was
significant [58,61,65,66]. On the basis of extensive clinical evidence, the adverse effects associated with
nabiximols treatment are referred as mild to moderate, and generally well tolerated. They include
drowsiness, dizziness, headache, fatigue, impaired balance and disturbance in attention [58–64,66].
Regarding disability and disease progression, clinical studies evidenced no significant changes in some
parameters, such as Barthel index of activity of daily living (ADL) and walking time (10 mt) [58,59].
Overall, these data indicate that nabiximols may represent a valid therapeutic options for pain,
spasticity, and quality of sleep in MS patients, with low incidence of adverse effects that are in general
not serious and well tolerated.
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3. Endocannabinoid System Modulators
3.1. CB1R and CB2R Ligands
Cannabinoids exert neuroprotective effects acting at multiple molecular sites that are in all key
cellular elements for the control of neuronal survival (e.g., neurons, astrocytes, resting and reactive
microglia, oligodendrocytes) and also in key brain structures (e.g., BBB) [84]. These effects are due to
activation of CB1R and CB2R.
CB1R is widely expressed within the CNS (cortical neurons and interneurons, oligodendrocytes,
astrocytes) and also in several leukocytes infiltrating the brain [85]. Initially CB2R has been restricted
exclusively to immune cells (macrophages, mast cells, B and T lymphocytes) and immune organs
(spleen, thymus, lymph nodes) [86]. However, some evidence showed the expression of CB2R in
microglia of the CNS [87], and more recently, it has been also reported to be expressed in brainstem
neurons and astrocytes upon cellular activation by an insult or inflammation [36,88,89].
The multiplicity of action of cannabinoids allows to reduce the excitotoxicity by acting through
neuronal CB1R, as well as the toxic influence of reactive microgliosis by acting through microglial CB2R,
or enhancing the trophic and metabolic support to neurons by acting through astroglial CB1R or CB2R.
In particular, the activation of CB1R provides neuroprotection regulating glutamate homeostasis [90].
In fact, it is well-known that glutamate is a key mediator in neuronal and oligodendrocyte damage
in MS [91], and CB1R agonists exert direct neuroprotective effects by limiting glutamate release and
the excitotoxic damage characteristic of several neurodegenerative disorders [92]. Furthermore, the
protective effects of CB2R activation in microglial cells upon inflammatory-induced CNS damage have
been demonstrated in preclinical models of multiple sclerosis [92]. Microglia may be, in two activated
states: M1 and M2. The classical M1 state is characterized by release of pro-inflammatory factors, i.e.,
interleukins (IL-1beta, IL-18, and IL-6), prostanoids and inducible nitric oxide synthase (NOS2)-derived
NO. On the other hand, the neuroprotective M2 state, known as “alternative activation” is associated
with the release of anti-inflammatory factors, such as IL-10, IL-4, and NGF [93]. Microglia has a
functional endocannabinoid signaling system, composed of cannabinoid receptors and the complete
machinery for the synthesis and degradation of endocannabinoids. The expression of cannabinoid
receptors, mainly CB2R, and the production of endocannabinoids have been related to the activation
profile of these cells [94].
In preclinical studies, the beneficial effects of cannabinoids have been reported in different
animal models of MS including experimental autoimmune encephalomyelitis (EAE), chronic relapsing
experimental allergic encephalomyelitis (CREAE), and Theiler’s murine encephalomyelitis virus
induced demyelinating disease (TMEV-IDD) [95]. More specifically, autoimmune encephalomyelitis is
a demyelinating autoimmune disease of the CNS that is characterized by mononuclear cell infiltration
and mainly induced by auto-reactive CD4+ T cells. EAE is a useful animal model of MS since many of
the pathologies observed in the CNS of mice with EAE show strong similarity to those found in the
CNS of MS patients [96]. CREAE animal model also presents relapsing-remitting paralytic episodes
and tremor and spasticity of limb muscles during post-relapse remission strongly similar to MS [97].
Finally, TMEV-IDD is an immune-mediated demyelinating disease dependent on persistent virus
infection of the macrophages, microglia and astrocytes within the CNS [98] and the inflammation and
demyelination observed in TMEV-IDD are similar to those described in MS patients [99].
One of the first studies of cannabinoids in MS model is reported by Lyman et al. in 1989 [100], who
demonstrated the effects of daily administration of ∆9-THC, a partial CB1R agonist with limited effects
on CB2R, on EAE progression in rats. Indeed, the development of EAE was ameliorated, indicating the
counteracting effect of ∆9-THC in the disease [100]. Subsequently, the effects of the phytocannabinoid
∆8-THC (Table 2) on EAE were studied by Wirguin et al. [101]. ∆8-THC is an analogue of ∆9-THC
which binds CB1Rs with high affinity and it is much more stable and less psychotropic than ∆9-THC.
In this study, ∆8-THC significantly ameliorated the clinical manifestations of EAE. Among all the
possible mechanisms of action postulated, one involved the inhibition of the prostanoid production by
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action of an active metabolite of ∆8-THC. This active metabolite would explain the necessity of the
oral, rather intraperitoneal administration due to the first-pass metabolism in the liver [101].
Further research deepened the study on the role of synthetic and endogenous cannabinoids in
CREAE animal model. Baker et al. showed evidence that cannabinoid CBRs agonists, in particular
R(+)-WIN 55212 (Table 2), ∆9-THC, methanandamide (Table 2) and JWH-133 (Table 2) quantitatively
ameliorated both tremor and spasticity in CREAE mice [102]. In order to address these effects to the
modulation of the ECS and with the aim to understand which of the CBRs was the most involved,
animals were pre-treated with CBRs selective antagonists. The results suggested a role of CB1R to
control tremor and an implication of both CBRs in the development of spasticity [102]. In the same
work was reported that the endocannabinoid palmitoylethanolamide (PEA) (Table 2) caused a transient
inhibition of spasticity [102]. However, more recently it was reported that co-administration of PEA
with CBD in EAE was not as active as treatment with each compound alone, indicating that these
non-psychoactive cannabinoids could have antagonistic interactions in EAE [103].
New findings indicated that cannabinoids could also target the development of progressive
forms of MS, using the TMEV-IDD model of disease [104]. In particular, in TMEV-infected mice,
WIN-55212-2 (Table 2), arachidonyl-2-chloroethylamide (ACEA), a selective CB1R agonist (Table 2),
and JWH-015, a weak selective CB2R agonist (Table 2), was demonstrated to improve motor function
on established neurological symptomatology, to promote the remyelination, and to reduce microglial
activation and the number of CD4+ infiltrated T cells [105]. Recent studies focused on the development
and study of CB2R selective agonists as the best therapeutic approach thanks to their lack of central
side effects usually associated with a CB1R modulation. Recent research aimed at the synthesis of
CB2R selective ligands bearing different chemical scaffolds to find new agents for the treatment of
MS. First of all, a resorcinol derivative, O-1966 (Table 2), was tested in the chronic EAE model. This
compound significantly improved motor function in the chronic EAE model, at concentration of 1 mg
kg−1. Moreover, O-1966 reduced rolling and adhesion of endogenous leukocytes [106].
1,4-dihydro-6-methylindeno[1,2-c]pyrazole derivative, Gp-1a (Table 2), with a four log higher
affinity for CB2R than for CB1R, was demonstrated to be able to reduce clinical scores and ameliorate
the recovery in EAE mice presenting a long term reduction in demyelination and axonal loss. Two
different mechanisms were established since it was able to affect Th1/Th17 differentiation in peripheral
immune organs and pathogenic T cell accumulation in the CNS and reduce the expression of chemokine
and adhesion molecules in the CNS [107].
Furthermore, in 2015, Fu et al. [108] showed that intrathecal administration of JWH-133 (Table 2),
a selective CB2R agonist, in EAE mice, dose-dependently reduced both mechanical and cold
hypersensitivity without any signs of ataxia or sedation. The co-administration of JWH-133 with a
selective CB2R antagonist dose-dependently attenuated the inhibitory effects of JWH-133. This data
suggested that the selective targeting of spinal CB2R reduced signs of neuropathic pain in EAE mice
without any side effects [108].
In the same year, Han et al. synthesized new quinoline-2,4(1H,3H)-dione derivatives as CB2R
agonists. Among all the synthesized derivatives, compound 21 (Table 2) was the one shown to
significantly reduce the clinical scores and symptoms of the mice EAE model, as shown by the
remarkably decreased leukocyte infiltration in the spinal cord and demyelination in white matter [109].
The following year, chromenopyrazole was identified as a promising scaffold to obtain CBRs
ligands [110]. Structural modifications have been studied in order to achieve CB2R selectivity and
the structural changes led to the synthesis of chromenoisoxazole derivative PM-226 (Table 2) that
was shown to be fully CB2R selective with a high affinity constant. PM-226 was found to dampen
neuroinflammation in the TMEV mouse model by reducing microglial activation to levels close to
those quantified in the control group [110]. This decrease in the microglia activation lead, as already
reported, to a reduction of inflammatory events and an improvement of the neurological status of
treated animals [111].
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In 2017, Ying Shi et al. reported the identification of new potent and selective indole based CB2R
agonists [112]. Compound 57 (Table 2) was selected as a representative analogue to be studied in a
mouse EAE model of MS. This compound was significantly shown to alleviate the clinical symptoms
and to protect the murine central nervous system from immune damage in EAE mouse model. Further
histological examination of spinal cords demonstrated significant reduction in leukocyte infiltration
and the extent of demyelination [112]. This study supporting again the efficacy of selective CB2R
agonists in animal models of MS.
Very recently, Navarrete et al. [113] provided evidence that VCE-004.8 (Table 2), an aminoquinone
derivative of cannabidiol (CBD), is a promising small molecule to modulate relevant MS targets,
being a dual PPARγ and CB2 agonist with potent anti-inflammatory activity. VCE-004.8 showed
immunomodulatory activity in EAE and TMEV mice models, inhibiting several inflammatory
chemokines, chemokines receptors, and cytokines that play a key role in the pathogenesis of MS.
In addition, VCE-004.8 inhibited the expression of adhesion molecules such as VCAM and ICAM-1.
Also remarkable is the finding that VCE-004.8 strongly induced the expression of the hypoxia-inducible
factor (HIF), which can have a beneficial role in MS by modulating the immune response and favoring
neuroprotection and axonal regeneration.
Regarding phytocannabinoids, excluding CBD and ∆9-THC, which are discussed in a specific
section of this review, the sesquiterpene β-caryophyllene (BCP) (Table 2) is worth mentioning. It is a
CB2R selective agonist already reported in literature for its anti-inflammatory and analgesic effects in
mouse models of inflammatory and neuropathic pain [114]. In a very recent work, BCP was shown
to attenuate disease progression by reducing mechanical hyperalgesia, inflammation, and pain in a
mouse EAE model [115]. In order to prove that BCP effects were due to its actions on CB2Rs, BCP was
co-administered with a selective CB2R antagonist, which reversed the BCP effects. Altogether, this
data suggested that BCP, binding to CB2R, blocks the development and progression of clinical and
neurological signs of EAE [115].
Table 2. Cannabinoid receptors (CBRs) ligands and their effects shown in different animal models of
MS (pertinent references are in parenthesis).
Structure and Name Origin and Activity Animal Model and Effects
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Gp-1a 
Synthetic cannabinoid  
CB2R agonist 
In EAE mice: reduction of clinical 
scores; amelioration of the recovery 
[107]. 
compound 21 
Synthetic cannabinoid  
CB2R agonist 
In EAE mice: reduction of the clinical 
scores and symptoms; decrease of 
leukocyte infiltration in the spinal cord 
and demyelination in white matter 
[109]. 
PM-226 
Synthetic cannabinoid  
CB2R agonist 
In TMEV-infected mice: dampening of 
neuroinflammation; reduction of 
microglial activation [110,111]. 
compound 57 
Synthetic cannabinoid  
CB2R agonist 
In EAE mice: alleviation of the clinical 
symptoms of EAE; protection of the 
murine central nervous system from 
immune damage; reduction of 
leukocyte infiltration and demyelination 
[112]. 
VCE-004.8 
 
Synthetic cannabinoid  
CB2R agonist 
In EAE and TMEV mice: 
immunomodulatory activity; inhibition 
of inflammatory chemokines, 
chemokines receptors, and cytokines; 
inhibition of the expression of adhesion 
molecules (VCAM and ICAM-1); 
induction of the expression of the 
hypoxia-inducible factor (HIF) [113]. 
β-caryophyllene (BCP)  Phytocannabinoid  
CB2R agonist 
In EAE mice: reduction of mechanical 
hyperalgesia, inflammation and pain 
[115]. 
3.2. Inhibitors of Metabolic Enzymes of ECs 
Alternative strategies to modulate ECS are focused on blocking the enzymes that degrade the 
two main endocannabinoid compounds (2-AG and AEA). This is an interesting therapeutic approach, 
as enhancing ECs levels is expected to preserve the beneficial effects derived from the direct 
activation of CBRs but limiting potential side effects mostly associated to direct CB1R agonists. It has 
been widely demonstrated that, in MS patients, there is a significant alteration of the metabolic 
enzymes mainly of FAAH and of MAGL [116,117]. 
The effects linked to alterations of the metabolism of endocannabinoids are not completely clear, 
also because of the different experimental models used and the variations in the recruitment of 
patients. Different studies in TMEV‐IDD mice have assessed that the inhibition of AEA degradation 
by FAAH determines an improvement of the motor symptoms, with a reduction of inflammatory 
response and the downregulation of macrophage and of microglial function [118,119]. Webb et al. 
have demonstrated, in tests carried out on an EAE mouse model, that chronic and long-term 
inhibition of FAAH, via genetic ablation, produces clinical remission and ameliorates long-term 
results [120]. Other researchers have shown that high levels of 2-AG can make improvements in the 
acute phase of MS. Indeed, 2-AG is able to inhibit spasticity when administered at dose of 10 mg kg−1 
Gp-1a
Synthetic cannabinoid
CB2R agonist
In EAE mice: reduction of clinical
scores; amelioration of the
recovery [107].
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compound 21
Synthetic cannabinoid
CB2R agonist
In EAE mice: reduction of the
clinical scores and symptoms;
decrease of leukocyte infiltration
in the spinal cord and
demyelination in white matter
[109].
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patients. Different studies in TMEV‐IDD mice have assessed that the inhibition of AEA degradation 
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P -226
Synthetic cannabinoid
CB2R agonist
In TMEV-infected mice:
dampening of neuroinflammation;
reduction of microglial activation
[110,111].
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have demonstrated, in tests carried out on an EAE mouse model, that chronic and long-term 
inhibition of FAAH, via genetic ablation, produces clinical remission and ameliorates long-term 
results [120]. Other researchers have shown that high levels of 2-AG can make improvements in the 
acute phase of MS. Indeed, 2-AG is able to inhibit spasticity when administered at dose of 10 mg kg−1 
compound 57
Synthetic inoid
CB2R ag i t
In EAE mic : lleviatio f t
cli ical symptoms of EAE;
protection of th muri e central
nervous system from immune
damage; reductio of leukocyte
infiltration and demyelination
[112].
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Synthetic cannabinoid
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I EAE nd TMEV mice:
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inhibiti n of inflammat ry
chemokines, ch mokines
receptors, and cytokines;
inhibition of the expression of
adhesion molecules (VCAM and
ICAM-1); induction of the
expression of the
hypoxia-inducible factor (HIF)
[113].
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3.2. Inhibitors of Metabolic Enzymes of ECs
Alternative strategi s to m dulate ECS are focused on blocking the enzymes that degrad the two
main ndocannabinoid compounds (2-AG a d AEA). This i a interesting therapeu ic approach, as
enhancing ECs levels is expected to pres rve the beneficial effects derived from the direct activation of
CBRs but limit g po ential side effects mos ly associated to irect CB1R agonists. It has b en widely
demonstrated that, in MS patients, th re is a signific nt alteration of the metabolic nzym s ainly of
FA H an of MAGL [116,117].
The eff cts linked to alterations of the metab lism of endocannabi oi s are ot compl tely clear,
ls b cause of the diff ren exp rimental models used and the variations in the recruitment of
patients. Different studies i TMEV-IDD ice have assessed that the inhibition of AEA degradation
by FAAH determin s n improvement of t e motor sympto s, with reduction of inflammatory
response and downregulation of macrop ge and of microglial function [118,119]. Webb et al. ave
demonstrated, in tests carried out on an EAE mouse model, that chro ic and long-term inhibition of
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FAAH, via genetic ablation, produces clinical remission and ameliorates long-term results [120]. Other
researchers have shown that high levels of 2-AG can make improvements in the acute phase of MS.
Indeed, 2-AG is able to inhibit spasticity when administered at dose of 10 mg kg−1 and determines a
delayed onset in acute and chronic EAE models when given at a concentration of 100 mg kg−1 [121].
The focus of the researchers has been mainly on the MAGL inhibitors, as 2-AG is the main
endocannabinoid present in the brain, and it is a full agonist of CB1R and CB2R. However,
Scholosburg et al. [122] have shown that increased levels of 2-AG in the brain, due to the
chronic MAGL inhibition, provokes a functional antagonism of the cerebral endocannabinoid
system [122]. This was evidenced with tolerance to the analgesic effects of acute enzymatic inhibition,
cross-tolerance to CB1R agonists, reduction of expression and function of the CB1R, and interruptions
in endocannabinoid-dependent synaptic plasticity.
In a recent work, the utility of irreversible MAGL inhibitor, JZL184, (Table 3), in the treatment
of MS has been demonstrated [123]. Indeed, the chronic administration of JZL184 reduced the
neurological consequences of disease progression in EAE mice. This result is linked to reduce of
myelin loss and of inflammation of spinal cord white matter [123]. Furthermore, it was demonstrated
that the repeated administration of JZL184 at a dose of 8 mg kg−1 did not provoke changes in CB1
receptor expression in the hippocampus. Moreover, there was not tolerance to the anxiolytic and
analgesic effects of the MAGL inhibitor [123].
Table 3. Inhibitors of metabolic enzymes of endocannabinoids (ECs) and their effects shown in different
animal models of multiple sclerosis (MS) (pertinent references are in parenthesis).
Structure and Name Activity Animal Model Effects
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lactam-based inhibitors reporting compound 4a (Table 3) as very potent hMAGL inhibitor, with high 
selectivity toward FAAH, other serine hydrolases, and CBRs [124]. This compound in EAE mice 
showed analgesic effects that were clearly dependent on the increased levels of 2-AG and the 
subsequent indirect modulation of CBRs. Moreover it exerted a surprising beneficial effect on the 
progression of the disease, thanks to the CB1R and CB2R mediated action, confirming the hypothesis 
of a close intersection between the endocannabinoid system and MS. Histological evaluation of 
myelin showed that, when the EAE mice were treated with compound 4a, myelin-density staining 
was comparable to that of control animals [124]. 
As the irreversible MAGL inhibition causes pharmacological tolerance and receptor 
desensitization, many researchers have focused on development of reversible inhibitors. An 
interesting example is given by the compound 21 (Table 3) synthesized by Hernández-Torres et al. 
[125]. This compound showed a submicromolar IC50 value for MAGL inhibition and very good 
selectivity against FAAH, ABDH6, and ABHD12 enzymes, the CB1R and CB2R cannabinoid 
receptors [125]. In AEA mouse, it was demonstrated its ability to significantly increase the levels of 
2-AG in spinal cord, improving clinical symptoms and decreasing tissue damage in the spinal cords. 
Importantly, catalepsy or other motor impairments that are observed after the administration of 
irreversible MAGL inhibitors, didn’t occurred. 
As reported above, the prolonged inhibition of MAGL enzymes, although effective, provokes 
negative effects that compromise its biological activity. These effects do not occur by FAAH inhibition. 
Indeed, it was demonstrated that the prolonged inhibition of FAAH produced no tolerance or no 
changes in the expression or function of the CB1 receptor [122]. 
Pryce et al. [126] studied the efficacy of FAAH inhibitors to control the spasticity in Biozzi ABH 
mice. They demonstrated that potent FAAH inhibitors such as CAY10402 (Table 3) and CAY10400 
(Table 3) inhibited spasticity but did not induce any hypothermia, typical of cannabimimetic effects. 
However, CAY10400 and CAY10402 have poor pharmacokinetics, and therefore, their development 
as therapeutic drugs is unlikely [126]. 
A valid alternative is given by compound URB597 (Table 3), which is a potent FAAH inhibitor 
irreversible, with improved pharmacokinetic profile [126]. Repeated administration of URB597 in a 
few days compared to the vehicle demonstrated that this compound induced spasticity alleviation 
immediately after administration, but spasticity was similarly inhibited after four daily doses. 
However, the study emphasized a benefit because the level of spasticity at baseline after four 
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the histological level, it reduced microglial activation, diminished major histocompatibility complex 
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confirm the role played by the ECS at the level of immunomodulation, and they are in agreement 
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With the aim to increase the pot n y of JZL184, Brindisi et al. described the synthesis of ew
β-lactam-based inhibitors reporting compound 4a (Table 3) as very potent hMAGL inhibitor, with
high sel ct vity toward FAAH, other serine hydrolases, and CBRs [124]. This compound in EAE
mice show d analges c effects that w r clearly dependent on the increased levels of 2-AG and the
subsequent indirect modulation of CBRs. Moreover it exerted a surprising beneficial ffect on the
progression of the disease, thanks to the CB1R and CB2R mediated action, confirming the hypothesis
of a close in ersection between the endocannabinoid sy tem and MS. Histological v luatio of myelin
show d that, when the EAE mice were treated with compound 4a, myelin-density staining was
comparable to that of control animals [124].
As t e irreversible MAGL inhibition causes ph rmac logical tolerance and r ceptor
de nsitization, many researchers have focused on development of rev rsible inhibitors. An interest g
example is given by the co pound 21 (Table 3) synthesized by Herná dez-Torres et l. [125]. This
compound showed a submicromolar IC50 value f r MAGL inhibition and v ry good selectivity against
FAAH, ABDH6, nd ABHD12 enzymes, the CB1R and CB2R cannabinoid receptors [125]. In AEA
mouse, it was demonstrated its abili y to significantly increase the levels of 2-AG in spinal cord,
improving clinical symptoms and decreasing t ssue damage in the spinal cords. Importantly, catalepsy
or other motor impairments that are observed after he administration of irreversible MAGL inhibitors,
didn’t occurred.
As reported above, the prolonged inhibition of MAGL enzymes, although effective, provokes
negative eff cts that compromise its biological activity. T ese effects do n t occur by FAAH inhibition.
Indeed, it was demonstrated that the prolonged inhibition of FAAH produced no tolerance or no
changes in the expres ion or function of the CB1 receptor [122].
Pryc et al. [126] studied the efficacy of FAAH inhibitors to control the spasticity in Biozzi ABH
mice. They demonstrated that potent FAAH inhibitors such as CAY10402 (Table 3) and CAY10400
(Table 3) inh bited sp sticity but did not induce any hypothermia, typical of cannabimimetic effects.
How , CAY10400 and CAY10402 h ve poor pharmacokinetics, and therefore, their development as
therapeutic drugs is unlikely [126].
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A valid alternative is given by compound URB597 (Table 3), which is a potent FAAH inhibitor
irreversible, with improved pharmacokinetic profile [126]. Repeated administration of URB597 in a
few days compared to the vehicle demonstrated that this compound induced spasticity alleviation
immediately after administration, but spasticity was similarly inhibited after four daily doses. However,
the study emphasized a benefit because the level of spasticity at baseline after four administrations
was lower than baseline before treatment. Moreover, the use of this inhibitor was not associated with
CB1R tolerance.
Another way to modulate the endocannabinoid system is to act on AEA reuptake, and many
selective inhibitors of cellular reuptake of AEA, but inactive against other enzyme involved in the
degradation of this endocannabinoid, have been developed. Ligresti et al. reported very interesting
inhibitors of endocannabinoid reuptake [127]. In particular, the most potent compound was O-3246
(Table 3), which has a very high potency as an inhibitor of AEA cellular uptake and a negligible activity
as an FAAH inhibitor, CB1R and CB2R ligand, and TRPV1 agonist. This compound was shown to
inhibit spasticity in CREAE mice, confirming the potential utility of selective AEA uptake inhibitors as
anti-spasticity drugs in MS [127].
Furthermore, it has been found that UCM707 (Table 3), a potent and selective inhibitor of the
AEA reuptake [119], was able to improve the motor function in a TMEV-IDD mouse model, and at
the histological level, it reduced microglial activation, diminished major histocompatibility complex
class II antigen expression, and decreased cellular infiltrates in the spinal cord [119]. These results
confirm the role played by the ECS at the level of immunomodulation, and they are in agreement with
experiments that describe how the blockade of microglial activation represses the development of the
EAE model of MS.
4. Conclusions
MS is a neurodegenerative disease affecting millions of people worldwide, yet there is no cure,
and the management of symptoms remains a clinical challenge. Recent findings highlight the fact that,
in animal models of MS, the modulation of distinct components of ECS (CBRs, degrading enzymes,
and AEA transporters) may represent a new and promising therapeutic strategy in the control of
symptoms and disease progression in MS. Relief of symptoms in MS by cannabinoids has been
reported to be mostly mediated by the activation of CB1R. This amelioration of spasticity can be
achieved by the elevation of the endogenous levels of endocannabinoids via inhibition of the AEA
transporter as well as by inhibition of the deactivating enzymes of AEA and/or of 2-AG, FAAH, and
MAGL, respectively. Moreover, the changes reported for the ECS in different MS models have been
associated with adaptive responses for limiting neuronal damage. In particular, the activation of CB1R
provides neuroprotection regulating glutamate homeostasis and excitotoxic damage. Furthermore,
the protective effects of CB2R activation in microglial cells upon inflammatory-induced CNS damage
have been demonstrated in preclinical models of MS. Finally, the enhancing trophic and metabolic
support to neurons through astroglial CB1R or CB2R allows us to reduce the excitotoxicity providing
neuroprotection. From these data, it is reasonable to assume that the simultaneous modulation of more
targets of ECS, combined with conventional therapies, might have more beneficial effects by acting
synergistically. This goal might be achieved by multi-target ECS modulators that can directly and
indirectly modulate cannabinoid receptor activity by exerting different mechanisms of action, thus
offering the possibility of modulating the ECS in a safer and more effective way than single target
modulation [128]. However, extensive preclinical studies of this kind molecule are needed, and only
positive results from these preclinical studies can lead to a possible clinical study. The multi-target
modulators of ECS could be able to control disease progression, and at the same time the symptoms of
multiple sclerosis, and might have a translational potential and could represent promising candidates
for clinical development.
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